STOCK TITAN
  1. Home
  2. News
  3. ORIC

Oric Pharmaceuticals, Inc. - ORIC STOCK NEWS

Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.

Oric Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to discovering and developing innovative therapies for the treatment of cancer. Headquartered in South San Francisco, California, Oric Pharmaceuticals was founded in 2014 and has since focused on addressing the challenging problem of cancer resistance to existing treatments.

The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor. This receptor has been identified as a key player in the resistance mechanisms against various classes of cancer therapeutics, particularly across solid tumors. By targeting this receptor, ORIC-101 aims to enhance the effectiveness of existing cancer treatments.

Another significant asset in Oric's pipeline is ORIC-533, an orally bioavailable small molecule inhibitor of CD73. CD73 plays a role in resistance to both chemotherapy and immunotherapy, and ORIC-533 is being developed to counteract this resistance, offering a potential new avenue for treating patients who do not respond to current therapies.

In addition to ORIC-101 and ORIC-533, the company is also developing ORIC-944 and ORIC-114, each targeting different mechanisms of cancer resistance. ORIC-944 has shown promise in initial Phase 1b data, and the company has outlined several anticipated milestones for these programs in the near future.

Oric Pharmaceuticals demonstrates a robust commitment to advancing the field of precision oncology. The company leverages its expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies to build a diverse pipeline of therapies. These efforts are supported by strategic partnerships and collaborations aimed at accelerating the development and commercialization of their treatment candidates.

Financially, Oric Pharmaceuticals has provided guidance and updates to keep stakeholders informed about their progress and strategic direction. For the latest news and developments, investors and interested parties are encouraged to stay tuned to the company's announcements.

Contact: Dominic Piscitelli, Chief Financial Officer

dominic.piscitelli@oricpharma.com

info@oricpharma.com

News

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (ORIC) will participate in two investor conferences in February, including the 6th Annual Guggenheim Biotechnology Conference and the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company's management will engage in fireside chats during these events, with webcasts and replays accessible through the investor section of ORIC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
conferences
-
News

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) has announced a private placement of approximately 12.5 million shares of its common stock to institutional and accredited healthcare specialist investors, at a price per share of $10.00. The financing is expected to raise approximately $125 million and is anticipated to fund the company's research and development activities into late 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
none
-
News

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced promising Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer, demonstrating a potential best-in-class profile. The company also highlighted operational achievements for 2023, including the initiation of multiple dose expansion cohorts for ORIC-114 and expected cash and investment to fund operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
clinical trial
News

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced that CEO Jacob M. Chacko, M.D. will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The company focuses on developing treatments for therapeutic resistance in oncology. A live webcast of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
conferences
-
News

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC) granted 23,080 non-qualified stock options and 3,840 restricted stock units to new non-executive employees. The options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. The grants are subject to vesting conditions and were approved by ORIC’s Compensation Committee as a material inducement to employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
none
-
News

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced its participation in investor conferences in November, including the Jefferies London Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference. The company will be hosting fireside chats and webcasts of the discussions and presentations will be available through the investor section of the company’s website at www.oricpharma.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
conferences
News

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Rhea-AI Summary
ORIC Pharmaceuticals, Inc. presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC, demonstrating a potential best-in-class profile. Initial Phase 1b data for ORIC-533 in patients with multiple myeloma will be presented at the 65th ASH Annual Meeting. Cash and investments of $256.2 million are expected to fund the operating plan into late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
earnings
-
News

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
ORIC Pharmaceuticals has granted 14,800 non-qualified stock options and 2,480 restricted stock units to a new non-executive employee. The grants were made under the 2022 Inducement Equity Incentive Plan and are subject to vesting conditions. The stock options have an exercise price equal to the closing price of ORIC's common stock on the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
-
News

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary
ORIC Pharmaceuticals, Inc. announced a poster presentation on the initial Phase 1b clinical data for ORIC-533 in patients with relapsed/refractory multiple myeloma at the 65th American Society of Hematology Annual Meeting. ORIC-533 is a highly potent and selective inhibitor of CD73, currently being evaluated in an ongoing Phase 1b study. The study included heavily pretreated patients and showed good tolerability, with no dose limiting toxicities or serious adverse events. Preliminary evidence of enhanced CD8+ T-cell activation and single agent clinical activity was observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
conferences clinical trial
News

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

Rhea-AI Summary
ORIC Pharmaceuticals announces initial data from the ORIC-114 Phase 1 trial for EGFR/HER2 exon 20 mutated NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of Oric Pharmaceuticals (ORIC)?

The current stock price of Oric Pharmaceuticals (ORIC) is $8.21 as of December 20, 2024.

What is the market cap of Oric Pharmaceuticals (ORIC)?

The market cap of Oric Pharmaceuticals (ORIC) is approximately 550.4M.

What is Oric Pharmaceuticals, Inc.?

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to treat cancer by overcoming resistance to current treatments.

What is ORIC-101?

ORIC-101 is a small molecule antagonist of the glucocorticoid receptor, aimed at combating resistance in various solid tumors to enhance the effectiveness of cancer treatments.

What is ORIC-533?

ORIC-533 is an orally bioavailable small molecule inhibitor of CD73, developed to address resistance to chemotherapy and immunotherapy regimens.

Where is Oric Pharmaceuticals headquartered?

Oric Pharmaceuticals is headquartered in South San Francisco, California.

When was Oric Pharmaceuticals founded?

Oric Pharmaceuticals was founded in 2014.

What other products are in Oric Pharmaceuticals' pipeline?

In addition to ORIC-101 and ORIC-533, Oric Pharmaceuticals is developing ORIC-944 and ORIC-114, which target different cancer resistance mechanisms.

What are the core areas of expertise for Oric Pharmaceuticals?

The company focuses on hormone-dependent cancers, precision oncology, and key tumor dependencies.

How can I contact Oric Pharmaceuticals for more information?

You can contact Dominic Piscitelli, the Chief Financial Officer, at dominic.piscitelli@oricpharma.com or info@oricpharma.com for more information.

What is the company’s financial condition?

Oric Pharmaceuticals regularly provides financial guidance and updates to inform stakeholders about their progress and strategic direction.

What recent achievements has Oric Pharmaceuticals made?

Recent achievements include initial Phase 1b data for ORIC-944 and progress in developing ORIC-533 as a potent inhibitor of CD73.

Stock ORIC logo
Oric Pharmaceuticals, Inc.

Nasdaq:ORIC

ORIC Rankings

#3022 Ranked by Market Cap
N/A Ranked by Dividends

ORIC Stock Data

550.42M
59.77M
9.4%
102.1%
16.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO